Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
8297- lign,    Pharmacokinetics of enterolignans in healthy men and women consuming a single dose of secoisolariciresinol diglucoside
- Trial, Nor, NA
*Dose?, *Half-Life↝, *Half-Life↝, *BioAv↝,
8299- lign,    Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer
- Trial, BC, NA
TumCG↓, Dose↝, Ki-67↓, Apoptosis↑,
7706- lpi,  NIV,    Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
- Trial, Melanoma, NA
OS↑,
8380- LT,    Luteolin, a bioactive compound from Celastrus orbiculatus stem, inhibits cervical cancer via CA2 suppression: A translational study bridging basic research and clinical application
- Trial, Cerv, NA
Dose↝, Ca+2↓,
8366- LT,    Preliminary Evidence on Safety and Clinical Efficacy of Luteolin for Patients With Prostate Cancer Under Active Surveillance
- Trial, Pca, NA
Dose↝, eff↑, SD↑, Ki-67↓, AR↓, NKX3.1↓, miR-29b↑, miR-30a-5p↑,
8351- Lut,  Zeax,    Lutein and Zeaxanthin Influence Brain Function in Older Adults: A Randomized Controlled Trial
- Trial, AD, NA
*Dose↝, *cognitive↑, *Learn↑, *neuroP↑,
8352- Lut,  Zeax,    The effects of lutein and zeaxanthin on resting state functional connectivity in older Caucasian adults: a randomized controlled trial
- Trial, AD, NA
*Dose↝, *cognitive↑,
8353- Lut,    Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial
- Trial, AD, NA
*Dose↝, *cognitive∅,
8355- Lut,  Zeax,    Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration
- Trial, AMD, NA
*Dose↝, *Dose↝, *eff↝, *eff↑,
8356- Lut,    Amount of fat in the diet affects bioavailability of lutein esters but not of alpha-carotene, beta-carotene, and vitamin E in humans
- Trial, Nor, NA
*BioAv↑, *Dose↝,
4193- Lut,  Zeax,    Effects of a Lutein and Zeaxanthin Intervention on Cognitive Function: A Randomized, Double-Masked, Placebo-Controlled Trial of Younger Healthy Adults
- Trial, Nor, NA
*MPOD↑, *cognitive↑, *memory↑,
4192- Lut,  Zeax,    Lutein and Zeaxanthin Supplementation Improves Dynamic Visual and Cognitive Performance in Children: A Randomized, Double-Blind, Parallel, Placebo-Controlled Study
- Trial, Nor, NA
*MPOD↑, *cognitive↑, *memory↑, *BDNF↑,
3982- Lut,  Zeax,    Nutritional Intervention to Prevent Alzheimer's Disease: Potential Benefits of Xanthophyll Carotenoids and Omega-3 Fatty Acids Combined
- Trial, AD, NA
*memory↑, *Synergy↑, *Mood↑,
3981- Lut,  Zeax,  VitE,    Omega-3 fatty acid, carotenoid and vitamin E supplementation improves working memory in older adults: A randomised clinical trial
- Trial, AD, NA
*memory↑, *other↑, *cognitive↑,
3980- Lut,  Zeax,    Supplementation With Carotenoids, Omega-3 Fatty Acids, and Vitamin E Has a Positive Effect on the Symptoms and Progression of Alzheimer's Disease
- Trial, AD, NA
*eff↑, *memory↑, *Mood↑, *QoL↑,
3979- Lut,    Increases in Plasma Lutein through Supplementation Are Correlated with Increases in Physical Activity and Reductions in Sedentary Time in Older Adults
- Trial, AD, NA
*other↑, *QoL↑,
3978- Lut,  Zeax,    Effects of Lutein/Zeaxanthin Supplementation on the Cognitive Function of Community Dwelling Older Adults: A Randomized, Double-Masked, Placebo-Controlled Trial
- Trial, AD, NA
*cognitive↑, *Inflam↓,
3977- Lut,  Zeax,    Dietary carotenoids related to risk of incident Alzheimer dementia (AD) and brain AD neuropathology: a community-based cohort of older adults
- Trial, AD, NA
*Aβ↓, *cognitive↑, *Mood↑,
3983- Lut,  Zeax,    The impact of supplemental macular carotenoids in Alzheimer's disease: a randomized clinical trial
- Trial, AD, NA
*other↑, *other↑, *cognitive∅,
8423- Lyco,  Rad,    Tomato Juice Consumption Could Improve Breast Skin Adverse Effects of Radiotherapy in Breast Cancer Patients
- Trial, BC, NA
Dose↝, radioP↑, 8-oxo-dG↓,
8422- Lyco,  Rad,    Dietary and Serum Lycopene Levels in Prostate Cancer Patients Undergoing Intensity-Modulated Radiation Therapy
- Trial, Pca, NA
Weight↑, other?, Dose↝, Dose↝, *Half-Life↝, radioP?,
8418- Lyco,  docx,    A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients
- Trial, Pca, NA
Dose↝, BioEnh↑, angioG↓, IGF-1↓, ChemoSen↑, BioAv↑, CEC↝,
8409- Lyco,    Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy
- Trial, Pca, NA
Risk↓, PSA↓, TumCG↓,
8408- Lyco,    Enhanced bioavailability of lycopene when consumed as cis-isomers from tangerine compared to red tomato juice, a randomized, cross-over clinical trial
- Trial, Nor, NA
*BioAv↑, *Dose↝,
7742- Lyco,  isoFl,    Lycopene and soy isoflavones in the treatment of prostate cancer
- Trial, Pca, NA
Risk↓, PSA↓, Dose↝, eff↝,
8727- M-Blu,    High absolute bioavailability of methylene blue given as an aqueous oral formulation
- Trial, Nor, NA
*Dose?, *BioAv↑,
8732- M-Blu,    Methylene blue for intractable pain from oral mucositis related to cancer treatment: a randomized phase 2 clinical trial
- Trial, Var, NA
Dose?, Mucositis↓, Pain↓,
8631- MBZ,  BEV,    Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer
- Trial, CRC, NA
Dose?, Synergy↑, PFS↑, VEGF↓, ChemoSen↑,
8637- MBZ,    Phase 1 study of mebendazole therapy for refractory/progressive or recurrent pediatric brain tumors
- Trial, MB, NA
Dose↝, toxicity↝, eff∅,
8790- mCHEMO,    Long-term outcomes of adjuvant metronomic capecitabine in locoregionally advanced nasopharyngeal carcinoma: a randomized, controlled, multicenter, phase 3 study
- Trial, NPC, NA
other↝, OS↑,
8795- mCHEMO,    Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study
- Trial, NPC, NA
other↝, OS↑, PFS↑, toxicity↝,
8785- mCHEMO,  capec,    Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial
- Trial, NPC, NA
Dose↝, OS↑, toxicity↝,
8791- mCHEMO,    Real-World Efficacy of Metronomic Chemotherapy in Advanced Breast Cancer Across Molecular Subtypes
- Trial, BC, NA
PFS?, OS↑, eff↑,
8792- mCHEMO,    Early capecitabine metronomic chemotherapy improves patient prognosis and safety in early-stage triple-negative breast cancer
- Trial, BC, NA
PFS↑, eff↑,
8820- MCP,    Effect of pectasol-c modified citrus pectin (P-MCP) treatment (tx) on PSA dynamics in non- metastatic biochemically relapsed prostate cancer (BRPC) patients (pts): Primary outcome analysis of a prospective phase II study.
- Trial, Pca, NA
toxicity↝, SD↝, PSA↓, PSADT↓, TumMeta∅,
8815- MCP,    Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension
- Trial, Nor, NA
Dose↝, Gal-3↓,
8814- MCP,    Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II Study
- Trial, Pca, NA
*toxicity↓, Gal-3?, PSADT↑, Dose↝, PSA↓, PSADT↑,
8813- MCP,    Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study
- Trial, Pca, NA
PSADT↑,
8824- MCP,    Clinical Benefit in Patients with Advanced Solid Tumors Treated with Modified Citrus Pectin: A Prospective Pilot Study
- Trial, Var, NA
toxicity↓, Dose↝, CR↑, QoL↑, SD↑, PSA↓,
3896- MCT,    Improvement of Main Cognitive Functions in Patients with Alzheimer's Disease after Treatment with Coconut Oil Enriched Mediterranean Diet: A Pilot Study
- Trial, AD, NA
*memory↑, *cognitive↑,
8709- MET,    Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer
- Trial, BC, NA
Risk∅, Dose↝, OS∅,
8712- MET,    Metformin Active Surveillance Trial in Low-Risk Prostate Cancer
- Trial, Pca, NA
Dose↝, Risk∅, eff∅,
8713- MET,    Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol
- Trial, Pca, NA
Dose↝, OS∅,
4095- MF,    Frequency-tuned electromagnetic field therapy improves post-stroke motor function: A pilot randomized controlled trial
- Trial, Stroke, NA
*Dose↝, *motorD↑,
4097- MF,    Theta Frequency Electromagnetic Stimulation Enhances Functional Recovery After Stroke
- Trial, Stroke, NA
*motorD↑, *eff↑, *Dose↝,
4098- MF,    Extremely low frequency electromagnetic field (ELF-EMF) reduces oxidative stress and improves functional and psychological status in ischemic stroke patients
- Trial, Stroke, NA
*antiOx↑, *cognitive↑, *Dose↝,
4099- MF,    Extremely low frequency electromagnetic field reduces oxidative stress during the rehabilitation of post-acute stroke patients
- Trial, Stroke, NA
*ROS↓,
3478- MF,    One Month of Brief Weekly Magnetic Field Therapy Enhances the Anticancer Potential of Female Human Sera: Randomized Double-Blind Pilot Study
- Trial, BC, NA - in-vitro, BC, MCF7 - in-vitro, Nor, C2C12
TumCP↓, TumCMig↓, TumCI↓, *toxicity∅, TGF-β↓, Twist↓, Slug↓, β-catenin/ZEB1↓, Vim↓, p‑SMAD2↓, p‑SMAD3↓, angioG↓, VEGF↓, selectivity↑, LIF↑,
6939- MF,    A prospective, randomized, placebo controlled, double-blind study of pelvic electromagnetic therapy for the treatment of chronic pelvic pain syndrome with 1 year of followup
- Trial, Nor, NA
*Pain↓,
6936- MF,  Ex,    Pulsed electromagnetic field with or without exercise therapy in the treatment of benign prostatic hyperplasia
- Trial, BPH, NA
*eff↑, *Synergy↑, *BloodF↑, *Diff↝, *Dose↝, *Dose↝, *Dose↝, *Dose↝, *Dose↝, *Dose↝, *Dose↝, *UFR↑, *UR↓, *PSA↓, *other↑, *Inflam↓,

Showing Research Papers: 351 to 400 of 542
Prev Page 8 of 11 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 542

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

NA↑, 2,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 2,   Bil∅, 1,   Copper↓, 2,   CoQ10↑, 1,   GSH↓, 1,   MDA↓, 1,   ROS↓, 3,   ROS↑, 5,   ROS↝, 2,   SOD↑, 1,   TrxR↓, 1,   VitC↑, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

selm↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

BCR-ABL↓, 1,   Insulin↓, 2,   PGC-1α↑, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

5LO↓, 1,   ALAT↓, 1,   FAO↑, 1,   lactateProd↓, 1,   PDK1 / PDPK1↓, 2,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 8,   Bcl-2↓, 3,   Bcl-xL↓, 2,   Cyt‑c↝, 1,   IAP1↓, 1,   Mcl-1↓, 3,   NOXA↑, 1,   Perforin↑, 1,   PUMA↑, 1,   survivin↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

ADCY4↑, 1,   p‑Akt↓, 1,   EGFR↓, 3,   IGF-2R↑, 1,   IGFR↓, 1,   PI3K↓, 1,   PTEN↑, 2,  

Transcription & Epigenetics(tgid=7) ⓘ

HDAC↓, 4,   miR-106b↓, 1,   miR-19b↓, 1,   miR-29b↑, 1,   miR-30a-5p↑, 1,   Myc↓, 1,   other?, 1,   other↓, 4,   other↑, 6,   other↝, 24,   other∅, 3,   SD↑, 5,   SD↝, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

NEU1↑, 1,   TumAuto↓, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

8-oxo-dG↓, 1,   NKX3.1↓, 1,   P53↑, 1,   RAD51↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cellSen?, 1,   cycD1/CCND1↓, 2,   Ki-67↓, 6,   P21↑, 3,   TumCCA↑, 5,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 1,   CSCs↓, 2,   HH↓, 3,   HH∅, 1,   IGF-1↓, 7,   IGF-1↑, 1,   IGFBP1↑, 2,   IGFBP3↓, 1,   IGFBP3↑, 1,   JAG1↑, 1,   Ki-67↓, 6,   NOTCH3↑, 1,   Smo↓, 1,   TumCG↓, 9,   TumCP↓, 11,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

AntiAg↝, 1,   AntiAg∅, 1,   Ca+2↓, 1,   Ca+2↑, 1,   GLI3↓, 1,   MMP2↓, 1,   MMP9↓, 2,   MMP9:TIMP1↑, 1,   Slug↓, 2,   p‑SMAD2↓, 1,   p‑SMAD3↓, 1,   Snail↓, 1,   TGF-β↓, 1,   TIMP1↓, 1,   TumCA↓, 3,   TumCI↓, 3,   TumCMig↓, 3,   TumMeta↓, 2,   TumMeta↑, 1,   TumMeta∅, 1,   Twist↓, 1,   Vim↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 9,   angioG∅, 1,   E-sel↓, 1,   Endoglin↓, 1,   Hif1a↓, 2,   PGI2↓, 1,   VEGF↓, 4,   VEGFR2/KDR/Flk1↑, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   IBI↑, 1,   MPT↑, 1,   TRPV1↑, 1,   ZO-1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

ALC↓, 1,   ANXA1↓, 1,   CD14↓, 1,   CD25+↓, 1,   CD4+↓, 1,   CD4+↑, 3,   CD8+↑, 5,   COX2/PTGS2↓, 4,   COX2/PTGS2∅, 1,   Eos↑, 1,   FoxP3+↓, 1,   Gal-3?, 1,   Gal-3↓, 1,   GM-CSF↓, 1,   IFN-γ↑, 2,   IL10↓, 1,   IL10↑, 1,   IL12↓, 1,   IL18↑, 1,   IL1β↓, 2,   IL1β∅, 1,   IL2↑, 1,   IL22↓, 1,   IL6↓, 4,   Imm↑, 12,   Imm⇅, 1,   Imm↝, 1,   INF-γ↝, 1,   Inflam↓, 9,   LIF↑, 1,   MCP1/CCL2↓, 1,   Neut↓, 1,   Neut↑, 2,   NF-kB↓, 4,   NK cell↑, 4,   PDT+↓, 1,   PGE2↓, 2,   PSA↓, 16,   T-Cell↑, 1,   TNF-α↓, 2,   TNF-α↑, 1,   TNF-α∅, 1,   VitD↑, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

BDNF↓, 1,   TrkB↓, 1,  

Protein Aggregation(tgid=19) ⓘ

AGEs↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

2/16-OHE1↓, 1,   2/16-OHE1↑, 1,   2/16-OHE1↝, 1,   ADRB2↓, 1,   AR↓, 3,   AR↝, 1,   DHT↓, 1,   ENL↑, 1,   EstroRS/ERS↑, 1,   PPARγ↓, 1,   SHBG↑, 1,   testos↓, 1,   testos∅, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↑, 10,   BioAv↝, 10,   BioEnh↑, 1,   ChemoSen↑, 8,   ChemoSen∅, 1,   CYP1A2↑, 1,   CYP3A4⇅, 1,   Dose?, 13,   Dose↓, 3,   Dose↑, 7,   Dose↝, 152,   Dose∅, 4,   eff↓, 3,   eff↑, 40,   eff↝, 8,   eff∅, 12,   Half-Life↑, 1,   Half-Life↝, 6,   P-gp/ABCB1↓, 2,   RadioS↑, 5,   selectivity↑, 5,   Synergy?, 1,   Synergy↑, 10,   Synergy∅, 1,   TET2↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   ALB∅, 1,   AR↓, 3,   AR↝, 1,   AST↓, 1,   BG↓, 1,   Bil∅, 1,   BUN↓, 1,   CA125↓, 1,   CA125∅, 1,   CA19-9↓, 1,   CEC↝, 1,   CIT↓, 1,   creat↓, 1,   CRP↓, 3,   CRP∅, 1,   CTC↓, 1,   EGFR↓, 3,   EstroRS/ERS↑, 1,   HemoG↑, 1,   IL6↓, 4,   Myc↓, 1,   Mye↓, 1,   NLR↓, 1,   PC↑, 3,   Polyps↓, 1,   PSA↓, 16,   PSADT↓, 1,   PSADT↑, 3,   RBC↑, 4,   UFR↑, 1,   Verbal↑, 2,   VitD↑, 1,   WBC↑, 2,  

Functional Outcomes(tgid=23) ⓘ

AEs∅, 1,   AntiCan↓, 1,   AntiCan↑, 6,   antiD↑, 4,   antiNeop↑, 2,   AntiTum↑, 4,   AntiTum∅, 1,   ANXi↓, 4,   APG↓, 2,   cachexia↓, 1,   cardioP↑, 4,   CardioT↑, 1,   CardioT↝, 1,   chemoP↑, 8,   chemoP∅, 1,   chemoPv↑, 5,   ChemoSideEff↓, 2,   cognitive↑, 1,   cognitive∅, 1,   CR↑, 5,   DCR↑, 5,   DCR↝, 1,   fatigue↓, 5,   fatigue∅, 1,   hepatoP↓, 1,   hepatoP↑, 2,   LC↑, 1,   mal↓, 1,   memory↑, 2,   Mood↑, 1,   Mucositis↓, 5,   Nausea↓, 4,   Nausea∅, 2,   neuroP↑, 1,   NP/CIPN↓, 2,   NP/CIPN↑, 3,   Obesity↓, 1,   ORR↑, 4,   ORR∅, 1,   OS?, 1,   OS↑, 55,   OS↝, 1,   OS∅, 11,   Pain↓, 9,   PFS?, 1,   PFS↑, 9,   PFS∅, 1,   QoL↑, 21,   QoL↝, 1,   QoL∅, 4,   radioP?, 1,   radioP↑, 5,   radioP↝, 1,   Remission↑, 3,   RFS↑, 1,   Risk↓, 14,   Risk↑, 2,   Risk↝, 2,   Risk∅, 6,   stomatitis↓, 1,   Strength↑, 1,   Strength∅, 1,   Stress↓, 1,   toxicity↓, 29,   toxicity↑, 1,   toxicity↝, 26,   toxicity∅, 1,   TTP↑, 1,   TumVol↓, 4,   TumW↓, 1,   Vomit↓, 4,   Vomit∅, 2,   Weight↑, 6,   Weight∅, 2,   Wound Healing↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

Diar↓, 1,   Diar⇅, 1,   GutMicro↑, 3,   Inf↓, 4,   Sepsis↓, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↑, 1,   Ingr↝, 4,  
Total Targets: 317

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

NA↓, 1,   NA↑, 1,   NA↝, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 2,   antiOx↑, 12,   Bil↓, 2,   Bil∅, 1,   Catalase↑, 1,   GPx↑, 1,   GSH↑, 5,   HDL↓, 2,   HDL↑, 4,   HO-1↑, 1,   Iron↓, 1,   Iron↑, 1,   lipid-P↓, 2,   MDA↓, 4,   MDA↑, 1,   MPOD↑, 2,   NRF2↑, 2,   PCO↓, 1,   ROS↓, 17,   SAM-e↓, 1,   SOD↑, 3,   TAC↑, 6,   TBARS↓, 1,   uricA↓, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

Insulin↓, 1,   mitResp↑, 1,   mtDam↓, 1,   PGC-1α↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

12-HETE↓, 1,   5-HETE↓, 1,   ACLY↓, 1,   AcOH↑, 2,   adiP↑, 1,   ALAT↓, 6,   ALAT↑, 1,   ALAT∅, 2,   AMPK↑, 1,   Buty↑, 4,   CRM↑, 1,   DHA↑, 2,   Eic↓, 1,   FFA/NEFA↓, 1,   FFA/NEFA↝, 1,   glucose↓, 1,   glucose∅, 1,   KeyT↝, 1,   lactateProd↓, 1,   LDL↓, 11,   lipidLev↓, 1,   NH3↓, 1,   PA↑, 2,   SCFAs↑, 3,   SCFAs∅, 1,   SIRT1↑, 1,   Uridine↑, 1,  

Cell Death(tgid=5) ⓘ

BAX↓, 1,   Casp3↓, 1,   p38↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

CK2↓, 1,   PI3K↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

AntiThr↑, 3,   DNMT3A↑, 1,   HDAC3↓, 1,   other?, 3,   other↓, 4,   other↑, 18,   other↝, 20,   other∅, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 1,   DNArepair↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Choline↑, 1,   Diff↝, 1,   EP2↑, 1,   IGF-1↓, 1,   IGF-1↑, 1,   IGFBP3↓, 1,   NOTCH↓, 1,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 5,   AntiAg∅, 1,   MMP9↓, 1,   TGF-β↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 1,   TXA2↓, 1,   VCAM-1↓, 1,   VEGF↑, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   IBI↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD14↑, 1,   COX1↓, 1,   Eos↓, 1,   IFN-γ↓, 1,   IFN-γ↑, 5,   IgA↑, 1,   IgE↓, 1,   IL1↓, 1,   IL10↓, 2,   IL10↑, 1,   IL10∅, 1,   IL12↓, 1,   IL17∅, 1,   IL1β↓, 6,   IL4↑, 1,   IL4∅, 1,   IL6↓, 12,   IL8↓, 1,   Imm↑, 7,   Inflam↓, 26,   IP-10/CXCL-10↓, 1,   MCP1/CCL2↓, 1,   MCP1/CCL2↝, 1,   MIP‑1α/CCL3?, 1,   NF-kB↓, 1,   NK cell↑, 5,   PGE2↓, 2,   PGE2∅, 1,   PSA↓, 1,   TNF-α↓, 9,   TNF-α↑, 3,   VitD↑, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5-AR↓, 1,   5HT↑, 3,   Ach↑, 2,   AChE↓, 5,   BDNF↑, 8,   BDNF∅, 1,   proBDNF↑, 1,   BrainVol↑, 1,   BrainVol↝, 1,   BrainVol∅, 3,   GABA↑, 1,   NGF↑, 2,  

Protein Aggregation(tgid=19) ⓘ

APOE4↑, 1,   Aβ↓, 10,   Aβ∅, 1,   BACE/β-secretase↓, 1,   tau↓, 3,   p‑tau↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

2/16-OHE1↑, 1,   cortisol↓, 1,   END↑, 1,   ENL↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 5,   BioAv↑, 22,   BioAv↝, 14,   Dose?, 20,   Dose↓, 1,   Dose↑, 8,   Dose↝, 143,   eff↓, 2,   eff↑, 20,   eff↝, 8,   eff∅, 1,   Half-Life↓, 2,   Half-Life↑, 2,   Half-Life↝, 20,   P450↓, 1,   Synergy↑, 6,  

Clinical Biomarkers(tgid=22) ⓘ

ADC↓, 1,   ALAT↓, 6,   ALAT↑, 1,   ALAT∅, 2,   ALB↑, 3,   ALP↓, 1,   AST↓, 4,   AST↑, 1,   AST∅, 2,   Bil↓, 2,   Bil∅, 1,   BloodF↑, 4,   BMD↑, 1,   BP↓, 12,   BP∅, 2,   Calcium↑, 1,   CCr / CrCl↓, 1,   CCr / CrCl∅, 1,   creat∅, 1,   CRP↓, 5,   FEV1↑, 2,   Hcy/homoC↓, 13,   Hcy/homoC↝, 1,   HemoG↑, 2,   HRV↑, 1,   hs-CRP↓, 2,   IL6↓, 12,   IRes↓, 1,   KeyT↝, 1,   LDH↓, 3,   NLR↓, 1,   PC∅, 1,   PEF↑, 1,   PSA↓, 1,   rHR↓, 1,   TC↓, 3,   TG/TAG↓, 3,   TMAO∅, 1,   UFR?, 1,   UFR↑, 1,   UR↓, 1,   Verbal↑, 2,   VitD↑, 1,   WBC∅, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 1,   antiAll↑, 2,   AntiCan↑, 2,   antiD↑, 3,   AntiDiabetic↑, 2,   AntiTum↑, 3,   ANXi↓, 5,   BDI↓, 1,   BowelM↑, 1,   cardioP↑, 6,   chemoP↑, 3,   cognitive?, 1,   cognitive↓, 1,   cognitive↑, 78,   cognitive↝, 2,   cognitive∅, 12,   fatigue↓, 2,   GFR↓, 1,   GFR∅, 1,   hepatoP↑, 8,   IPSS↓, 1,   IPSS↝, 1,   Learn↑, 1,   memory↑, 26,   memory∅, 1,   Mood↑, 10,   motorD↑, 13,   MusCon↓, 1,   neuroP↑, 13,   NMSS↓, 1,   Obesity↓, 3,   OS↑, 1,   Pain↓, 12,   QoL?, 1,   QoL↑, 13,   RenoP↑, 3,   Risk↓, 6,   Risk↑, 2,   Risk↝, 1,   RT↓, 2,   Sleep↑, 12,   Strength↑, 4,   Stress↓, 6,   Tinn↓, 1,   toxicity↓, 40,   toxicity↑, 1,   toxicity↝, 4,   toxicity∅, 7,   UPDRS↓, 1,   UPDRSIII∅, 1,   Weight↓, 1,   Wound Healing↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiBio↑, 2,   AntiFungal↑, 2,   AntiViral↑, 4,   Bacteria↓, 2,   GutMicro↑, 10,   GutMicro∅, 1,   Inf↓, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 8,  
Total Targets: 266

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page